Short Interest in GlucoTrack Surges Over 600%

Shares of the medical device company see significant increase in short positions

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

GlucoTrack, Inc. (NASDAQ:GCTK), a medical device company focused on non-invasive glucose monitoring, saw a dramatic 634.6% increase in short interest in January, with short positions now accounting for 23.3% of the company's shares.

Why it matters

The sharp rise in short interest could indicate growing investor skepticism about GlucoTrack's prospects, despite the potential demand for its non-invasive glucose monitoring technology. This trend bears watching as it may signal broader market concerns about the company's performance or outlook.

The details

As of January 30th, there was short interest totaling 234,255 shares of GlucoTrack, up from 31,889 shares on January 15th. Based on the company's average daily trading volume of 1,698,025 shares, the days-to-cover ratio is currently 0.1 days, meaning short sellers could theoretically cover their positions in less than a day.

  • On January 30th, GlucoTrack had 234,255 shares sold short.
  • On January 15th, GlucoTrack had 31,889 shares sold short.

The players

GlucoTrack, Inc.

A medical device company focused on the design, development, and commercialization of non-invasive glucose monitoring technologies for people with diabetes.

Bank of America Corp DE

An institutional investor that recently increased its stake in GlucoTrack, now owning about 0.85% of the company's shares.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The surge in short interest in GlucoTrack's stock could signal growing market skepticism about the company's prospects, despite the potential demand for its non-invasive glucose monitoring technology. Investors will be closely watching to see how the company responds to this increased short activity and whether it can overcome any underlying concerns about its performance or outlook.